Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences has a better P/E ratio of 305.37 than the aggregate P/E ratio of 65.67 of the Biotechnology industry. Ideally, one might believe that Gilead Sciences Inc. might perform better in the ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...

Fueled by growth in its civil litigation business and government-facing practices, Wilmer's PEP rose more than 5% to $3.27 ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

Under U.S. law, most patents are limited to a term of 20 years from the earliest nonprovisional filing date. However, Patent Term Adjustment (PTA) ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...